KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results US launch of EKTERLY gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient st

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

US launch of EKTERLY gaining strong momentum with $13.7 million in net product

revenue for the third quarter

937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE)

Launched EKTERLY in Germany with initial

orders signaling encouraging demand

$309M in cash expected to fund the Company through profitability

Management to host conference call Tuesday, November 11th at 8:30 a.m. ET

FRAMINGHAM, Mass. & SALISBURY, England, November 10, 2025 - KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided

an operational update and reported financial results for the third quarter ended September 30, 2025.

"The US launch of EKTERLY is progressing

with significant momentum, driven by strong early demand and rapid adoption among physicians and people living with HAE. We continue to see encouraging trends, with both new patient starts and repeat prescriptions increasing consistently, reflecting

sustained uptake and confidence in the clinical value of EKTERLY as the first and only oral on-demand treatment for hereditary angioedema," said Ben Palleiko, CEO of KalVista. "We also recently

launched EKTERLY in Germany, with very positive initial demand. And with our most recent approval in Australia, we now hold five regulatory approvals and are on our way to making EKTERLY a truly global product. With the successful closing of our

recent $144 million convertible note offering, we have the financial resources to continue advancing our global launch strategy and building long-term growth."

Recent Business Highlights

EKTERLY (sebetralstat) Commercial Progress and Clinical Highlights

Organizational Updates

Third Quarter Financial Results

Earnings Conference Call and Webcast

KalVista management will host a conference call and webcast to discuss the results at 8:30 a.m. ET on Tuesday, November 11, 2025. The live audio webcast

will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event.

About EKTERLY (sebetralstat)

EKTERLY (sebetralstat) is a novel plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom, Switzerland and Australia for the

treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. EKTERLY is the first and only oral on-demand treatment for HAE, offering efficacious and safe treatment of attacks

without the burden of injections.

With ongoing studies exploring its use in children aged two to 11 and multiple regulatory applications under review in key global markets, EKTERLY has the potential to become the foundational

therapy for HAE management worldwide. For more information, including the full U.S. Prescribing Information, visit EKTERLY.com.

KalVista Pharmaceuticals, Inc.

KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals

affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY -the first and only oral on-demand

treatment for hereditary angioedema (HAE)-and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project,"

"estimate," "expect," "position," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These

statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, information relating to our business and business

plans, the success of our efforts to commercialize EKTERLY , including revenues from sales of EKTERLY, our ability to successfully obtain additional foreign regulatory approvals for

sebetralstat, our expectations about the safety and efficacy of sebetralstat and our other product candidates, the timing of clinical trials and their results, our ability to commence clinical studies or complete ongoing clinical studies, including

our KONFIDENT-S and KONFIDENT-KID trials, the ability of EKTERLY to treat HAE, and the future progress and potential success of our oral Factor XIIa program. Further

information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K

for the year ended April 30, 2025, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to

publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Head, Investor Relations

Director, Corporate Communications

KALVISTA PHARMACEUTICALS, INC.

Consolidated Balance Sheets

(in thousands except share and per share amounts)

KALVISTA PHARMACEUTICALS, INC.

Consolidated Statements of Operations

(in thousands, except share and per share amounts)